Amgen (AMGN) PT Lowered to $216 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Amgen (AMGN) PT Lowered to $250 at Jefferies
November 3, 2021 8:03 AM EDTJefferies analyst Michael Yee lowered the price target on Amgen (NASDAQ: AMGN) to $250.00 (from $270.00) while maintaining a Buy rating.
The analyst commented, "here were, and still are, worries about AMGN numbers, given no big guidance raises all year, and co says ongoing... More
